Previous 10 | Next 10 |
home / stock / nvsef / nvsef news
Introduction Precision BioSciences ( DTIL ) is a genome editing company dedicated to improving life through their proprietary genome editing platform (“ARCUS”), where they are developing product candidates in three high-value areas: allogeneic CAR T immunotherapy, in vivo g...
Quick Take Imara ( IMRA ) has filed to raise $86.25 million in an IPO of its common stock, according to an A-1 registration statement . The company is a clinical stage firm developing treatments for genetic disorders of hemoglobin. IMRA is an early Phase 2 biopharma with an expected pot...
This article is part of a series that provides an ongoing analysis of the changes made to David Einhorn's Greenlight Capital 13F portfolio on a quarterly basis. It is based on Einhorn's regulatory 13F Form filed on 02/14/2020. Please visit our Tracking David Einhorn's Greenlight Capital Hol...
Quick Take Revolution Medicines ( RVMD ) intends to raise $150 million from the sale of its common stock, according to an amended registration statement. The company is in Phase 1/2 trials for the development of treatments for various types of cancers. RVMD has produced promising early r...
Novartis Revenue Jumps but Net Income Falls for Q4 Novartis ( NVS ) posted mixed numbers for its fourth quarter. The company announced strong revenue growth but showed negative impact of higher taxes. Its core operating income for the quarter stood at $3.46 billion, up 11 percent while i...
Quick Take Beam Therapeutics ( BEAM ) intends to raise $100 million from the sale of its common stock, per an amended registration statement . The company is advancing a pre-clinical set of programs for the treatment of various diseases that may possibly be treated via gene editing of a s...
Quick Take Arcutis Biotherapeutics ( ARQT ) intends to raise $125 million from the sale of its common stock in an IPO, per an amended registration statement . The company is advancing a pipeline of treatment candidates for various skin conditions. For its lead candidate, ARQT plans to h...
Looking for a pharmaceutical industry overview? Let’s start with the world’s biggest pharmaceutical markets, the US and Europe. All of the biggest pharma companies on Pharmaceutical Technology’s list of the 10 top pharmaceutical companies by market share are ...
Quick Take Aditx Therapeutics ( ADTX ) has filed to raise $10.5 million in an IPO of its common stock and warrants, according to an S-1 registration statement . The company is a pre-clinical developer of immune suppression drugs to assist in organ transplantation procedures. ADTX is sti...
The 180-day lockup period for Castle Biosciences Inc . ( CSTL ) ends on January 21, 2020 . When the lockup ends, company's pre-IPO shareholders and insiders may choose to sell more than 10.4 million shares of CSTL in the secondary market. The number of currently-restricted shares dwarfs the ...
News, Short Squeeze, Breakout and More Instantly...
Novartis Ag Basel Akt Company Name:
NVSEF Stock Symbol:
OTCMKTS Market:
Novartis Ag Basel Akt Website:
FDA approval of the company’s second US Radioligand Therapy (RLT) manufacturing facility increases RLT production capacity to 250,000 doses in 2024 and beyond New 70,000-square foot RLT facility is the company’s largest and most advanced in the world to date and centrall...
APPLY-PNH extension data show that continuous Fabhalta ® (iptacopan) treatment in adults with paroxysmal nocturnal hemoglobinuria (PNH) enabled sustained hemoglobin-level increases to near-normal (≥12 g/dL), blood transfusion avoidance, and improved patient-reported fatigu...
With 5.6 months of additional follow-up and 78.3% of patients having completed Kisqali ® (ribociclib) investigational treatment, the updated analysis shows sustained iDFS benefit and stability in secondary endpoints including overall survival (OS) 1,2 iDFS...